Viking Therapeutics
A clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders.
Launch date
Employees
Market cap
€6.3b
Enterprise valuation
€5.5b (Public information from Sep 2024)
Share price
$68.16 VKTX
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 2.5m | 39.2m |
| % growth | - | - | - | - | - | - | 1468 % |
| EBITDA | (42.7m) | (55.7m) | (70.3m) | (101m) | (142m) | (176m) | (220m) |
| % EBITDA margin | - | - | - | - | - | (7028 %) | (562 %) |
| Profit | (39.5m) | (55.0m) | (68.9m) | (85.9m) | (110m) | (176m) | (201m) |
| % profit margin | - | - | - | - | - | (7040 %) | (512 %) |
| EV / revenue | - | - | - | - | - | 2535.2x | 162.3x |
| EV / EBITDA | -3.8x | -2.8x | -8.0x | -14.9x | -43.5x | -36.1x | -28.9x |
| R&D budget | 31.9m | 45.0m | 54.2m | 63.8m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$2.5m | Debt | ||
| N/A | N/A | IPO | |
| N/A | $12.5m | Post IPO Equity | |
| N/A | $14.8m | Post IPO Equity | |
* | N/A | $141m | Post IPO Equity |
* | N/A | $250m | Post IPO Equity |
* | N/A | $550m | Post IPO Equity |
| Total Funding | - | ||
Recent News about Viking Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.